162 related articles for article (PubMed ID: 33480655)
1. Vision Outcomes for Pediatric Patients With Optic Pathway Gliomas Associated With Neurofibromatosis Type I: A Systematic Review of the Clinical Evidence.
Thirunavu VM; Mohammad LM; Kandula V; Beestrum M; Lam SK
J Pediatr Hematol Oncol; 2021 May; 43(4):135-143. PubMed ID: 33480655
[TBL] [Abstract][Full Text] [Related]
2. Optic Pathway Gliomas in Neurofibromatosis Type 1.
Campen CJ; Gutmann DH
J Child Neurol; 2018 Jan; 33(1):73-81. PubMed ID: 29246098
[TBL] [Abstract][Full Text] [Related]
3. Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments.
Amato A; Imbimbo BP; Falsini B
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5636-5653. PubMed ID: 37401302
[TBL] [Abstract][Full Text] [Related]
4. Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children.
Ullrich NJ; Prabhu SP; Packer RJ; Goldman S; Robison NJ; Allen JC; Viskochil DH; Gutmann DH; Perentesis JP; Korf BR; Fisher MJ; Kieran MW;
Pediatr Blood Cancer; 2021 Apr; 68(4):e28833. PubMed ID: 33336845
[TBL] [Abstract][Full Text] [Related]
5. Visual Outcomes After Treatment for Sporadic Optic Pathway Gliomas in Pediatric Patients: A Systematic Review.
Shlobin NA; Montgomery EY; Mohammad LM; Kandula V; Beestrum M; DeCuypere M; Lam SK
World Neurosurg; 2022 Aug; 164():436-449.e2. PubMed ID: 35430402
[TBL] [Abstract][Full Text] [Related]
6. Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision.
de Blank PMK; Fisher MJ; Liu GT; Gutmann DH; Listernick R; Ferner RE; Avery RA
J Neuroophthalmol; 2017 Sep; 37 Suppl 1(Suppl 1):S23-S32. PubMed ID: 28806346
[TBL] [Abstract][Full Text] [Related]
7. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.
Segal L; Darvish-Zargar M; Dilenge ME; Ortenberg J; Polomeno RC
J AAPOS; 2010 Apr; 14(2):155-8. PubMed ID: 20451859
[TBL] [Abstract][Full Text] [Related]
8. Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.
Freret ME; Gutmann DH
J Neurosci Res; 2019 Jan; 97(1):45-56. PubMed ID: 29704429
[TBL] [Abstract][Full Text] [Related]
9. Natural history of optic pathway gliomas in a cohort of unselected patients affected by Neurofibromatosis 1.
Trevisson E; Cassina M; Opocher E; Vicenzi V; Lucchetta M; Parrozzani R; Miglionico G; Mardari R; Viscardi E; Midena E; Clementi M
J Neurooncol; 2017 Sep; 134(2):279-287. PubMed ID: 28577031
[TBL] [Abstract][Full Text] [Related]
10. Visual function assessed by visually evoked potentials in optic pathway low-grade gliomas with and without neurofibromatosis type 1.
Dotto PF; Berezovsky A; Cappellano AM; da Silva NS; Sacai PY; Silva FAB; Fernandes AG; Rocha DM; Salomão SR
Doc Ophthalmol; 2018 Jun; 136(3):177-189. PubMed ID: 29766345
[TBL] [Abstract][Full Text] [Related]
11. Optic Pathway Glioma and Cerebral Focal Abnormal Signal Intensity in Patients with Neurofibromatosis Type 1: Characteristics, Treatment Choices and Follow-up in 134 Affected Individuals and a Brief Review of the Literature.
Friedrich RE; Nuding MA
Anticancer Res; 2016 Aug; 36(8):4095-121. PubMed ID: 27466519
[TBL] [Abstract][Full Text] [Related]
12. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis.
Fisher MJ; Loguidice M; Gutmann DH; Listernick R; Ferner RE; Ullrich NJ; Packer RJ; Tabori U; Hoffman RO; Ardern-Holmes SL; Hummel TR; Hargrave DR; Bouffet E; Charrow J; Bilaniuk LT; Balcer LJ; Liu GT
Neuro Oncol; 2012 Jun; 14(6):790-7. PubMed ID: 22474213
[TBL] [Abstract][Full Text] [Related]
13. Neurofibromatosis Type 1-Associated Optic Pathway Glioma in Children: A Follow-Up of 10 Years or More.
Kinori M; Armarnik S; Listernick R; Charrow J; Zeid JL
Am J Ophthalmol; 2021 Jan; 221():91-96. PubMed ID: 32283094
[TBL] [Abstract][Full Text] [Related]
14. Visual acuity of children treated with chemotherapy for optic pathway gliomas.
Kalin-Hajdu E; Décarie JC; Marzouki M; Carret AS; Ospina LH
Pediatr Blood Cancer; 2014 Feb; 61(2):223-7. PubMed ID: 23956233
[TBL] [Abstract][Full Text] [Related]
15. Visual outcome following chemotherapy for progressive optic pathway gliomas.
Shofty B; Ben-Sira L; Freedman S; Yalon M; Dvir R; Weintraub M; Toledano H; Constantini S; Kesler A
Pediatr Blood Cancer; 2011 Sep; 57(3):481-5. PubMed ID: 21241008
[TBL] [Abstract][Full Text] [Related]
16. Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program.
Dalla Via P; Opocher E; Pinello ML; Calderone M; Viscardi E; Clementi M; Battistella PA; Laverda AM; Da Dalt L; Perilongo G
Neuro Oncol; 2007 Oct; 9(4):430-7. PubMed ID: 17704361
[TBL] [Abstract][Full Text] [Related]
17. Feasibility and comparison of visual acuity testing methods in children with neurofibromatosis type 1 and/or optic pathway gliomas.
Avery RA; Bouffet E; Packer RJ; Reginald A
Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1034-8. PubMed ID: 23329671
[TBL] [Abstract][Full Text] [Related]
18. Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1.
de Blank PM; Berman JI; Liu GT; Roberts TP; Fisher MJ
Neuro Oncol; 2013 Aug; 15(8):1088-95. PubMed ID: 23658320
[TBL] [Abstract][Full Text] [Related]
19. NF1 optic pathway glioma: analyzing risk factors for visual outcome and indications to treat.
Azizi AA; Walker DA; Liu JF; Sehested A; Jaspan T; Pemp B; Simmons I; Ferner R; Grill J; Hargrave D; Driever PH; Evans DG; Opocher E;
Neuro Oncol; 2021 Jan; 23(1):100-111. PubMed ID: 32628746
[TBL] [Abstract][Full Text] [Related]
20. Long-term visual outcome after chemotherapy for optic pathway glioma in children: Site and age are strongly predictive.
Dodgshun AJ; Elder JE; Hansford JR; Sullivan MJ
Cancer; 2015 Dec; 121(23):4190-6. PubMed ID: 26280460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
